Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Stock Competitors & Peer Comparison

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TAK has a market cap of 55.9B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TAK trades at $17.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TAK's P/E ratio is 12.63. In terms of profitability, DCPH's ROE is -0.56%, compared to TAK's ROE of +0.02%. Regarding short-term risk, DCPH is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TAK's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, HLN has a market cap of 43.8B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while HLN trades at $9.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas HLN's P/E ratio is 24.88. In terms of profitability, DCPH's ROE is -0.56%, compared to HLN's ROE of +0.17%. Regarding short-term risk, DCPH is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check HLN's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TEVA has a market cap of 42.1B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TEVA trades at $36.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TEVA's P/E ratio is 12.33. In terms of profitability, DCPH's ROE is -0.56%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, DCPH is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TEVA's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while VTRS trades at $16.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas VTRS's P/E ratio is 6.46. In terms of profitability, DCPH's ROE is -0.56%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, DCPH is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check VTRS's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ITCI's P/E ratio is -180.64. In terms of profitability, DCPH's ROE is -0.56%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, DCPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check ITCI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CTLT's P/E ratio is -27.84. In terms of profitability, DCPH's ROE is -0.56%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, DCPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check CTLT's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ELAN trades at $22.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ELAN's P/E ratio is 21.03. In terms of profitability, DCPH's ROE is -0.56%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, DCPH is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ELAN's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while RDY trades at $12.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas RDY's P/E ratio is 19.91. In terms of profitability, DCPH's ROE is -0.56%, compared to RDY's ROE of +0.09%. Regarding short-term risk, DCPH is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check RDY's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while LNTH trades at $100.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas LNTH's P/E ratio is 16.97. In terms of profitability, DCPH's ROE is -0.56%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, DCPH is similarly volatile compared to LNTH. This indicates similar risk in terms of short-term price fluctuations for DCPH.Check LNTH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AMRX trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AMRX's P/E ratio is 20.16. In terms of profitability, DCPH's ROE is -0.56%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, DCPH is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check AMRX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while INDV trades at $38.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas INDV's P/E ratio is 10.54. In terms of profitability, DCPH's ROE is -0.56%, compared to INDV's ROE of -2.16%. Regarding short-term risk, DCPH is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check INDV's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SUPN trades at $47.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SUPN's P/E ratio is 15.38. In terms of profitability, DCPH's ROE is -0.56%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, DCPH is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SUPN's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while RGC trades at $5.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas RGC's P/E ratio is -371.83. In terms of profitability, DCPH's ROE is -0.56%, compared to RGC's ROE of -2.32%. Regarding short-term risk, DCPH is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check RGC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while BHC trades at $6.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas BHC's P/E ratio is 1.62. In terms of profitability, DCPH's ROE is -0.56%, compared to BHC's ROE of +0.89%. Regarding short-term risk, DCPH is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check BHC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while HCM trades at $12.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas HCM's P/E ratio is 4.70. In terms of profitability, DCPH's ROE is -0.56%, compared to HCM's ROE of +0.01%. Regarding short-term risk, DCPH is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check HCM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, DCPH's ROE is -0.56%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, DCPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check AVDL's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas EMBCV's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.56%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, DCPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check EMBCV's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas DVAX's P/E ratio is -41.89. In terms of profitability, DCPH's ROE is -0.56%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, DCPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check DVAX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ANIP trades at $75.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ANIP's P/E ratio is 9.52. In terms of profitability, DCPH's ROE is -0.56%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, DCPH is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ANIP's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PRGO has a market cap of 1.7B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PRGO trades at $12.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PRGO's P/E ratio is 5.06. In terms of profitability, DCPH's ROE is -0.56%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, DCPH is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check PRGO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TARO's P/E ratio is 30.05. In terms of profitability, DCPH's ROE is -0.56%, compared to TARO's ROE of +0.03%. Regarding short-term risk, DCPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check TARO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while HROW trades at $40.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas HROW's P/E ratio is 452.22. In terms of profitability, DCPH's ROE is -0.56%, compared to HROW's ROE of -0.34%. Regarding short-term risk, DCPH is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check HROW's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PAHC trades at $34.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PAHC's P/E ratio is 11.66. In terms of profitability, DCPH's ROE is -0.56%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, DCPH is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check PAHC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ALVO trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ALVO's P/E ratio is -11.21. In terms of profitability, DCPH's ROE is -0.56%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, DCPH is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ALVO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ETON trades at $43.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ETON's P/E ratio is -623.86. In terms of profitability, DCPH's ROE is -0.56%, compared to ETON's ROE of -0.06%. Regarding short-term risk, DCPH is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ETON's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CRON has a market cap of 1.1B. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CRON trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CRON's P/E ratio is 28.49. In terms of profitability, DCPH's ROE is -0.56%, compared to CRON's ROE of +0.06%. Regarding short-term risk, DCPH is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check CRON's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PCRX has a market cap of 961M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PCRX trades at $24.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PCRX's P/E ratio is 9.40. In terms of profitability, DCPH's ROE is -0.56%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, DCPH is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check PCRX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PETQ's P/E ratio is 83.73. In terms of profitability, DCPH's ROE is -0.56%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, DCPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check PETQ's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AMPH trades at $20.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AMPH's P/E ratio is 7.09. In terms of profitability, DCPH's ROE is -0.56%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, DCPH is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check AMPH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, COLL has a market cap of 882.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while COLL trades at $27.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas COLL's P/E ratio is 3.41. In terms of profitability, DCPH's ROE is -0.56%, compared to COLL's ROE of +0.16%. Regarding short-term risk, DCPH is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check COLL's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, EVO has a market cap of 738.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while EVO trades at $2.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas EVO's P/E ratio is -2.94. In terms of profitability, DCPH's ROE is -0.56%, compared to EVO's ROE of -0.24%. Regarding short-term risk, DCPH is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check EVO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, IRWD has a market cap of 666.7M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while IRWD trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas IRWD's P/E ratio is 5.19. In terms of profitability, DCPH's ROE is -0.56%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, DCPH is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check IRWD's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas BDSI's P/E ratio is 6.82. In terms of profitability, DCPH's ROE is -0.56%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, DCPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check BDSI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AQST has a market cap of 538.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AQST trades at $4.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AQST's P/E ratio is -7.03. In terms of profitability, DCPH's ROE is -0.56%, compared to AQST's ROE of +1.91%. Regarding short-term risk, DCPH is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check AQST's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, EOLS has a market cap of 498.5M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while EOLS trades at $7.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas EOLS's P/E ratio is -23.97. In terms of profitability, DCPH's ROE is -0.56%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, DCPH is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check EOLS's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TLRY has a market cap of 494.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TLRY trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TLRY's P/E ratio is -6.97. In terms of profitability, DCPH's ROE is -0.56%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, DCPH is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TLRY's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, KMDA has a market cap of 411.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while KMDA trades at $7.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas KMDA's P/E ratio is 20.40. In terms of profitability, DCPH's ROE is -0.56%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, DCPH is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check KMDA's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CGC has a market cap of 401.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CGC trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CGC's P/E ratio is -0.57. In terms of profitability, DCPH's ROE is -0.56%, compared to CGC's ROE of -0.33%. Regarding short-term risk, DCPH is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check CGC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TKNO has a market cap of 360.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TKNO trades at $6.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TKNO's P/E ratio is -21.68. In terms of profitability, DCPH's ROE is -0.56%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, DCPH is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TKNO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ALIM's P/E ratio is 5.28. In terms of profitability, DCPH's ROE is -0.56%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, DCPH is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ALIM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, EMBC has a market cap of 296M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while EMBC trades at $4.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas EMBC's P/E ratio is 1.92. In terms of profitability, DCPH's ROE is -0.56%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, DCPH is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check EMBC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas LNDC's P/E ratio is -4.04. In terms of profitability, DCPH's ROE is -0.56%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, DCPH is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check LNDC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ORGO trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ORGO's P/E ratio is 62.00. In terms of profitability, DCPH's ROE is -0.56%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, DCPH is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ORGO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TYHT's P/E ratio is -1.61. In terms of profitability, DCPH's ROE is -0.56%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, DCPH is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TYHT's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SIGA has a market cap of 210.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SIGA trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SIGA's P/E ratio is 10.85. In terms of profitability, DCPH's ROE is -0.56%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, DCPH is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SIGA's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ACB has a market cap of 179M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ACB trades at $2.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ACB's P/E ratio is -5.90. In terms of profitability, DCPH's ROE is -0.56%, compared to ACB's ROE of -0.21%. Regarding short-term risk, DCPH is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ACB's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas REPH's P/E ratio is -8.04. In terms of profitability, DCPH's ROE is -0.56%, compared to REPH's ROE of -0.22%. Regarding short-term risk, DCPH is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check REPH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, DERM has a market cap of 177.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while DERM trades at $6.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas DERM's P/E ratio is -17.41. In terms of profitability, DCPH's ROE is -0.56%, compared to DERM's ROE of -0.36%. Regarding short-term risk, DCPH is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check DERM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, LFCR has a market cap of 174.8M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while LFCR trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas LFCR's P/E ratio is -4.36. In terms of profitability, DCPH's ROE is -0.56%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, DCPH is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check LFCR's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CRDL has a market cap of 169.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CRDL trades at $1.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CRDL's P/E ratio is -5.23. In terms of profitability, DCPH's ROE is -0.56%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, DCPH is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check CRDL's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas THTX's P/E ratio is -28.83. In terms of profitability, DCPH's ROE is -0.56%, compared to THTX's ROE of +0.17%. Regarding short-term risk, DCPH is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check THTX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ASRT's P/E ratio is -7.10. In terms of profitability, DCPH's ROE is -0.56%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, DCPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check ASRT's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, OGI has a market cap of 145M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while OGI trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas OGI's P/E ratio is -3.96. In terms of profitability, DCPH's ROE is -0.56%, compared to OGI's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check OGI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CPIX has a market cap of 116.7M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CPIX trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CPIX's P/E ratio is -19.47. In terms of profitability, DCPH's ROE is -0.56%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, DCPH is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check CPIX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SCTL's P/E ratio is -7.86. In terms of profitability, DCPH's ROE is -0.56%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, DCPH is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SCTL's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PROC's P/E ratio is 1.53. In terms of profitability, DCPH's ROE is -0.56%, compared to PROC's ROE of -2.22%. Regarding short-term risk, DCPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check PROC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas OPTN's P/E ratio is -4.42. In terms of profitability, DCPH's ROE is -0.56%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, DCPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check OPTN's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ZOM's P/E ratio is -1.62. In terms of profitability, DCPH's ROE is -0.56%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, DCPH is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ZOM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas GRVI's P/E ratio is 26.05. In terms of profitability, DCPH's ROE is -0.56%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, DCPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check GRVI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZYBT has a market cap of 85.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ZYBT trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ZYBT's P/E ratio is -8.18. In terms of profitability, DCPH's ROE is -0.56%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, DCPH is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ZYBT's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, DCPH's ROE is -0.56%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, DCPH is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ZYNE's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SSIC's P/E ratio is 11.93. In terms of profitability, DCPH's ROE is -0.56%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, DCPH is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SSIC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas VLNS's P/E ratio is -1.03. In terms of profitability, DCPH's ROE is -0.56%, compared to VLNS's ROE of N/A. Regarding short-term risk, DCPH is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check VLNS's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, BGM has a market cap of 59.6M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas BGM's P/E ratio is -1.02. In terms of profitability, DCPH's ROE is -0.56%, compared to BGM's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check BGM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas DRRX's P/E ratio is -4.44. In terms of profitability, DCPH's ROE is -0.56%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, DCPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check DRRX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, INCR has a market cap of 56.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while INCR trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas INCR's P/E ratio is -2.22. In terms of profitability, DCPH's ROE is -0.56%, compared to INCR's ROE of -0.09%. Regarding short-term risk, DCPH is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check INCR's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas JUPW's P/E ratio is -2.41. In terms of profitability, DCPH's ROE is -0.56%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, DCPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check JUPW's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas QLI's P/E ratio is -4.92. In terms of profitability, DCPH's ROE is -0.56%, compared to QLI's ROE of -0.16%. Regarding short-term risk, DCPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check QLI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas HEXO's P/E ratio is -0.26. In terms of profitability, DCPH's ROE is -0.56%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, DCPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check HEXO's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TLPH has a market cap of 28.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TLPH trades at $1.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TLPH's P/E ratio is -4.55. In terms of profitability, DCPH's ROE is -0.56%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, DCPH is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TLPH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, RMTI has a market cap of 27M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while RMTI trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas RMTI's P/E ratio is -6.51. In terms of profitability, DCPH's ROE is -0.56%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, DCPH is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check RMTI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AYTU has a market cap of 25.5M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AYTU trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AYTU's P/E ratio is -1.24. In terms of profitability, DCPH's ROE is -0.56%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, DCPH is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check AYTU's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while TXMD trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas TXMD's P/E ratio is 105.45. In terms of profitability, DCPH's ROE is -0.56%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, DCPH is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check TXMD's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CYTH's P/E ratio is -0.80. In terms of profitability, DCPH's ROE is -0.56%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, DCPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check CYTH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas EVOK's P/E ratio is -7.97. In terms of profitability, DCPH's ROE is -0.56%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, DCPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check EVOK's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, DCPH's ROE is -0.56%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, DCPH is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check BFRIW's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, OPTH has a market cap of 15.7M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while OPTH trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas OPTH's P/E ratio is -17.82. In terms of profitability, DCPH's ROE is -0.56%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, DCPH is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check OPTH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ACRX's P/E ratio is -0.31. In terms of profitability, DCPH's ROE is -0.56%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, DCPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ACRX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas COSM's P/E ratio is -0.36. In terms of profitability, DCPH's ROE is -0.56%, compared to COSM's ROE of -0.96%. Regarding short-term risk, DCPH is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check COSM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas AGRX's P/E ratio is -0.89. In terms of profitability, DCPH's ROE is -0.56%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, DCPH is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check AGRX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas NLTX's P/E ratio is -0.28. In terms of profitability, DCPH's ROE is -0.56%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, DCPH is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check NLTX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas LCI's P/E ratio is -0.04. In terms of profitability, DCPH's ROE is -0.56%, compared to LCI's ROE of +1.66%. Regarding short-term risk, DCPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check LCI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ADMP's P/E ratio is -0.08. In terms of profitability, DCPH's ROE is -0.56%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, DCPH is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check ADMP's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas YCBD's P/E ratio is -1.39. In terms of profitability, DCPH's ROE is -0.56%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, DCPH is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check YCBD's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, GELS has a market cap of 5.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while GELS trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas GELS's P/E ratio is -1.17. In terms of profitability, DCPH's ROE is -0.56%, compared to GELS's ROE of -0.25%. Regarding short-term risk, DCPH is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check GELS's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas MNK's P/E ratio is -0.44. In terms of profitability, DCPH's ROE is -0.56%, compared to MNK's ROE of -0.26%. Regarding short-term risk, DCPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check MNK's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, UPC has a market cap of 4.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while UPC trades at $7.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas UPC's P/E ratio is -0.86. In terms of profitability, DCPH's ROE is -0.56%, compared to UPC's ROE of -0.03%. Regarding short-term risk, DCPH is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check UPC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas FLGC's P/E ratio is -0.19. In terms of profitability, DCPH's ROE is -0.56%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, DCPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check FLGC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CPHI trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CPHI's P/E ratio is -1.76. In terms of profitability, DCPH's ROE is -0.56%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, DCPH is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check CPHI's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SBFM trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SBFM's P/E ratio is -0.20. In terms of profitability, DCPH's ROE is -0.56%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, DCPH is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SBFM's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PLXP's P/E ratio is -0.22. In terms of profitability, DCPH's ROE is -0.56%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, DCPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check PLXP's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SHPH trades at $4.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SHPH's P/E ratio is -0.19. In terms of profitability, DCPH's ROE is -0.56%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, DCPH is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SHPH's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas ATNX's P/E ratio is -0.02. In terms of profitability, DCPH's ROE is -0.56%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, DCPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check ATNX's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SNOA trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SNOA's P/E ratio is -1.09. In terms of profitability, DCPH's ROE is -0.56%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, DCPH is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SNOA's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas PROCW's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.56%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, DCPH is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check PROCW's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, SXTC has a market cap of 1.9M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while SXTC trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas SXTC's P/E ratio is 1.28. In terms of profitability, DCPH's ROE is -0.56%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, DCPH is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check SXTC's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, RDHL has a market cap of 1.8M. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while RDHL trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas RDHL's P/E ratio is 0.12. In terms of profitability, DCPH's ROE is -0.56%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, DCPH is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check RDHL's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, DCPH's ROE is -0.56%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, DCPH is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for DCPH.Check YCBD-PA's competition here

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DCPH stands at 2.2B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, DCPH is priced at $25.59 on the NASDAQ, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DCPH currently has a P/E ratio of -11.58, whereas CYTHW's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.56%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, DCPH is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for DCPH.Check CYTHW's competition here